Duo Venous Stent System
Philips Image Guided Therapy Corporation · Decision date Nov 18, 2025
What did the FDA approve?
FDA records P230021/S002 as a supplement to PMA P230021, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Nov 18, 2025.
FDA approval order statement
Approval for a design ownership and legal manufacturer located at Philips Image Guided Therapy Corporation (Philips), 5905 Nathan Lane North, Plymouth, MN 55442 and 9965 Federal Drive, Colorado Springs, CO 80921 USA
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 18, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230021/S002
- Regulatory pathway
- PMA supplement
- Product code
- QAN
- Decision code
- APPR
- Decision date
- Nov 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, iliac vein.
- Product code
- QAN
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230021/S002 received
Application receipt date recorded by FDA.
P230021/S002 · FDA decision
Normal 180 Day Track No User Fee
P230021/S003 · Related supplement
Duo Venous Stent System
P230021/S004 · Related supplement
Duo Venous Stent System
Timeline entries are records held by MedtechLedger for P230021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Duo Venous Stent SystemP230021/S003 | Philips Image Guided Therapy Corporation | PMA supplement | Feb 12, 2026 | FDA |
Duo Venous Stent SystemP230021/S004 | Philips Image Guided Therapy Corporation | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code QAN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Abre Venous Self-expanding Stent SystemP200026/S020 | Medtronic Vascular, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Abre Venous Self-Expanding Stent SystemP200026/S019 | Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Venovo Venous Stent SystemP180037/S015 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S018 | Medtronic Vascular, Inc. | PMA supplement | Apr 27, 2026 | FDA |
Zilver Vena Venous Self-Expanding StentP200023/S009 | Cook Ireland, Ltd. | PMA supplement | Apr 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Philips Image Guided Therapy Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5905 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P230021/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




